A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- Pfizer
- Study ID
- NCT05583526
- Phase
- PHASE3
- Status
- Completed
Conditions
- Active Nonsegmental Vitiligo
- Stable Nonsegmental Vitiligo
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Ritlecitinib — DRUG50 mg capsule
- Placebo — DRUGMatching capsule
Study Details
A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo
Key Dates
- Start date
- Dec 1, 2022
- Status verified
- Feb 2026
- Primary completion
- Feb 5, 2026
- Completion
- Feb 5, 2026
Study Design
- Enrollment
- 607 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Ritlecitinib 50 mgRitlecitinib 50 mg QD (ritilecitinib 50 mg QD arm; approximately 400 participants)
- Placebo Comparator: PlaceboPlacebo (placebo arm; approximately 200 participants)
Primary Outcome Measure
US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and T-VASI50 at Week 52 [ Time Frame: Week 52 ]
Locations (46)
Find similar trials in Birmingham, AL
By research site
University of Alabama at Birmingham· Birmingham, ALUniversity of Alabama at Birmingham Faculty Office Towers (Regulatory· Birmingham, ALCalifornia Dermatology & Clinical Research Institute· Encinitas, CAMarvel Clinical Research· Huntington Beach, CAWallace Medical Group, Inc· Los Angeles, CAAudiology· Washington D.C., DC